Regeneron's Profit Took A Hit, And Still Pounded Forecasts
Update: 2025-10-28
Description
Regeneron's stock surged 12% after a strong third-quarter report, beating Wall Street's expectations on sales and earnings. Eylea, Regeneron's top-selling eye medication, drove the growth, with sales exceeding forecasts despite competition from Roche's Vabysmo. Regeneron's total sales hit $3.75 billion, and adjusted earnings landed at $11.83 per share. However, a rejection letter from the FDA for a high-dose Eylea prefilled syringe caused a slight delay in its rollout. Regeneron plans to resubmit its request in January, aiming for approval by May.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
